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Received March 4, 2015; accepted June 1, 2015AbstractBackground: Video-assisted thoracoscopic surgery (VATS) with decortication is a major treatment for thoracic empyema in the fibropurulent
stage. Compared to open thoracotomy, VATS decortication has similar efficacy but fewer postoperative complications in the treatment of
thoracic empyema. The role of VATS decortication in the elderly had rarely been investigated.
Methods: From January 2006 to August 2011, we retrospectively enrolled 33 patients older than 65 years diagnosed as thoracic empyema and
treated with VATS decortication. We analyzed the outcomes of this geriatric population, including surgical effectiveness, postoperative
morbidity, and mortality.
Results: A total of 33 patients with mean age of 73.6 ± 7.1 years received VATS decortication for their empyema. Twenty-one (63.6%) patients
were male. Only one patient died of progressive sepsis, due to pulmonary infection 9 days after VATS decortication. The 30-day mortality was
3% after the surgery. The major etiology (87.9%) of thoracic empyema was pneumonia. The main causes of postoperation morbidity included
respiratory failure requiring mechanical ventilation for >7 days (15.2%) and septic shock (15.2%), followed by persistent air leakage for >7 days
(9.1%). Twenty-four (75%) of 32 patients had good re-expansion of the affected lung 3 months after VATS decortication.
Conclusion: We concluded that VATS decortication in the treatment of thoracic empyema is effective in elderly patients. The major concerns of
postoperative complications are respiratory failure and sepsis.
Copyright © 2015 Elsevier Taiwan LLC and the Chinese Medical Association. All rights reserved.
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1726-4901/Copyright © 2015 Elsevier Taiwan LLC and the Chinese Medical Asstreatment.1 Many studies have revealed increasing case
numbers of empyema in elderly patients.2,3 There are three
stages of empyema, exudative (Stage I), fibropurulent (Stage
II), and organizational (Stage III), which present a continuous
course of inflammatory process and should be managed by
different medical interventions.4 The exudative stage can usu-
ally be handled with tube drainage and appropriate antibiotic
treatment, and seldom needed surgical intervention.5 The sec-
ond fibropurulent or third organizational stage often needed
tube thoracotomy or surgical decortication because of fibrinociation. All rights reserved.
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pyema was 10e20%.6e8 The treatment of empyema needs
adequate antibiotic use and drainage by tube thoracotomy or
surgical intervention according to the particular empyema stage
and the patient's condition.6e8 Recently, an increasing number
of studies have favored the approach of video-assisted thor-
acoscopic (VATS) decortication in thoracic empyema
treatment.9e12 One study displayed VATS decortication with a
higher successful treatment rate (91% vs. 44%) and shorter
hospital stay (8.7 days vs. 12.8 days) compared with the group
with tube thoracotomy alone.13 A meta-analysis,14 which
reviewed 14 large studies, showed VATS decortication had
shorter total hospital stay (15 days vs. 21 days, p ¼ 0.03) and
fewer postoperation complications, such as atelectasis
( p ¼ 0.006) and mortality ( p ¼ 0.02), when compared with
open decortication. However, the role of VATS decortication in
the older population had been rarely reported. Considering the
worldwide trend of aging population society in the near future,
the best strategy to treat aging and fragile patients with thoracic
empyema should be further investigated. Therefore, this study
analyzed the outcome and complications of thoracic empyema
in older patients treated by VATS decortication in our hospital.
2. Methods2.1. Study populationTable 1
Demographic data of patients.
Cases (%), n ¼ 33
Age (y) 73.6 ± 7.1 (65e87)
Male sex 21 (63.6)
Charlson Comorbidity Index
0 2 (6.0)
1 10 (30.3)This was a retrospective study in National Yang-Ming
University Hospital, Yilan City, Taiwan, a 400-bed regional
teaching hospital that offers clinical services. From January
2006 to August 2011, we collected those patients with thoracic
empyema and treated with VATS decortication. The patient
inclusion criteria were (1) older than 65 years; (2) a patient of
thoracic empyema; and (3) accepted VATS decortication.
Exclusion criteria included patients under long-term ventilator
support and patients with septic shock and cardiopulmonary
distress. Pleural fluid was obtained by tube thoracotomy or
thoracentesis. The definition of empyema was satisfying at
least one of the following criteria: (1) pus-like material in the
pleural cavity; (2) a positive report of Gram stain or pleural
effusion culture for the microorganisms; and (3) pleural
effusion analysis with pH  7.2, glucose level  40 mg/dL,
and lactic dehydrogenase (LDH) level  1000 U/L.15 We
reviewed the demographic data, comorbidities, clinical
symptoms, images, and laboratory data, including pleural fluid
and culture report, for evaluation of the morbidity and mor-
tality. The study was approved by the authors' institutional
review board (IRB No. 2010A015).2 6 (18.1)
3 7 (21.2)2.2. Surgical technique
4 5 (15.2)
5 2 (6.0)
6 1 (3.0)
Stage of thoracic empyema
Exudative (Stage I) 5 (15.2)
Fibropurulent (Stage II) 24 (72.7)
Organizational (Stage III) 4 (12.1)
Values are presented as n (%) or mean ± standard deviation (range).We performed VATS decortication with general anesthesia
using double-lumen endotracheal tube insertion. After skin
preparation and sterilization, two incisions over the lesion site
with a 1-cm-length wound in the crossing of the eighth
intercostal space and the midaxillary line for camera, and
another 3-cm-length wound in the anteriorly fifth intercostalspace for access. Also, the two incision wounds allowed sur-
gical instruments to deal with the empyema.14,16 The decor-
tication was performed using forceps and scissors by a well-
experienced chest surgeon.142.3. Statistical analysisStatistical analyses were performed using SPSS software
version 15.0 (SPSS, Inc., Chicago, IL, USA). The patient data
were described by frequency for categorical variables, and by
mean ± standard deviation for numeric variables.
3. Results3.1. Patient characteristicsIn total, 33 patients older than 65 years accepted VATS de-
cortications for thoracic empyema. The characteristics of the 33
patients are listed in Table 1. The mean age was 73.6 ± 7.1
years. Twenty-one (63.6%) patients were male. The preopera-
tive comorbidities of the 33 patients were presented with the
Charlson comorbidity index. Twenty-four (72.7%) of the em-
pyema patients were categorized as being in the fibropurulent
stage, five (15.2%) were in the exudative stage, and four
(12.1%) were in the organizational stage.4 The laboratory data
showed a mean white blood cell count of 16.1 ± 8.9  109/L,
and mean C reactive protein of 21.5 ± 11.1 mg/dL. The most
common symptoms were cough (78.8%), followed by fever
(72.67%; Table 2). The major etiology of thoracic empyema
was pneumonia (87.9%; Table 2).3.2. Pleural effusion analysisIn thoracic empyema, we found 14/31 (45.2%) patients
with positive Gram stain or culture of pleural effusion (Table
3). All enrolled patients received antibiotic treatment before
VATS because of the clinical presentation of fever, cough, and
lung opacities by chest images during the initial hospitaliza-
tion. The most common pathogens were Klebsiella pneumonia
Table 2
Clinical presentation and etiology of thoracic empyema.
Cases (%), n ¼ 33
Clinical presentation
Fever 24 (72.7)
Cough 26 (78.8)
Dyspnea 21 (63.6)
Chest pain 17 (51.5)
Etiology for thoracic empyema
Post pneumonia 29 (87.9)
Trauma 2 (6.1)
Tuberculosis 2 (6.1)
Coexisting lung abscess 11 (33.3)
Values are presented as n (%).
Table 4
Pleural fluid laboratory analysis.
Cases
Leukocyte count ( 109/L) 13.5 ± 19.7 (n ¼ 24)
Protein (g/dL) 4.2 ± 1.2 (n ¼ 22)
LDH (U/L) 2951 ± 4380 (n ¼ 24)
Glucose (g/dL) 51.2 ± 53.6 (n ¼ 20)
Values are presented as mean ± standard deviation.
LDH ¼ lactic dehydrogenase.
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baumannii (3 patients).
In pleural effusion laboratory analysis (Table 4), the mean
white blood cell count was 13.5 ± 19.7  109/L, mean LDH of
2951 ± 4380 U/L, and mean glucose level of 51.2 ± 53.6 mg/
dL.3.3. Radiologic analysisThe postoperative chest plain radiographs and computed
tomography images were reviewed by radiologists and pul-
monologists in comparison with the preoperative images. The
final decisions on staging of empyema before surgery, disease
improvement or progression on discharge, and partial or good
expansion of the affected lung 90 days after discharge were
determined by consensus.173.4. Postoperative morbidity and mortalityTable 5
Postoperative complications and recovery evaluation.
Cases (%), n ¼ 33
Hospital length of stay (d) 27.5 ± 14.5
Postoperative length of stay (d) 17.9 ± 11.1
Tube drainage duration (d) 15.6 ± 20.4The mean hospital stay was 27.5 ± 14.5 days. Only one
patient died of progressive sepsis, due to pulmonary infection
9 days after VATS decortication. The 30-day mortality was 3%
after the surgery. Two patients (6.2%) had recurrent or
persistent empyema, and we performed mini-thoracotomy on
them 3 months later. The main postoperative morbidities
included respiratory failure requiring mechanical ventilation
for >7 days (15.2%) and septic shock (15.2%), followed by
persistent air leakage for >7 days (9.1%; Table 5). Twenty-
seven (84.4%) of 32 patients were stable on discharge, andTable 3
Microbiological data of thoracic empyema.
Cases (%), n ¼ 31
Gram-stain or culture (þ) from pleural effusion 14 (45.2)
Pathogen isolated from pleural effusion
Klebsiella pneumoniae 3 (9.7)
Streptococcus spp. 3 (9.7)
Acinetobacter baumannii 3 (9.7)
Staphylococcus aureus 2 (6.5)
Pseudomonas aeruginosa 1 (3.2)
Serratia spp. 1 (3.2)
Escherichia coli 1 (3.2)
Values are presented as n (%).24 (75%) of these patients had good expansion of the affected
lung 3 months after VATS decortication.
4. Discussion
In our study, we found that in aged patients (older than 65
years) with thoracic empyema, VATS decortication is an
effective treatment. The most common complications after
VATS decortication were respiratory failure and sepsis.
Older people usually have atypical presentation of thoracic
empyema, with less chest pain and fever but more dyspnea
than younger patients, which makes empyema early diagnosis
difficult.18 Due to age-related physiologic function decline and
comorbidities, older patients often have higher mortality rate
with thoracic empyema.2 Mandal et al19 reported that the
mortality rate is 50% in patients older than 65 years, compared
with patients younger than 65 years (only 3.6% mortality).
The older patients in the current study were classified as
moderate (Category 3) or high (Category 4) risk for a poor
outcome according to American College of Chest Physicians
(ACCP) guideline,20 but we had a lower post-VATS mortality
rate and acceptable morbidities. A study in Taiwan in 2005
revealed that the overall 100-day-in-hospital mortality for
thoracic empyema in older patients (>65 years) was 13% and
only 8% in younger patients.17 The empyema mortality of
older patients seems to have improved in recent decades,Postoperative complications
Mechanical ventilation (d) 7.2 ± 8.2
Respiratory failure 13 (39.4%)
Need for tracheostomy 5 (15.2%)
Septic shock 5 (15.2%)
Persistent air-leak >7 d 3 (9.1%)
Postoperative condition on discharge (n ¼ 32)
Disease remission 3 (9.4%)
Disease stable 27 (84.4%)
Disease progression 2 (6.2%)
Re-expansion of affected lung
On discharge Day 90 (n ¼ 32)
Good expansion 24 (75.0%)
Partial expansion 4 (12.5%)
Lost to follow-up 4 (12.5%)
Values are presented as n (%) or mean ± standard deviation.
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and health care improvements.18,21
VATS decortication uses less operation time and fewer
hospital days compared with open decortication.5,12 One large
series of thoracic decortications comparing VATS and open
procedures for 420 patients revealed the operation time in
VATS decortication was 97 minutes, while in open decorti-
cation it was 155 minutes ( p < 0.001).5 The median post-
operative stay was shorter for VATS decortication patients
compared with open decortication patients (7 days vs. 10 days,
p < 0.001). In addition, there were fewer postoperative com-
plications, such as atelectasis and reintubation in the VATS
decortication group.5,14 In our study, the mean hospital stay
was longer (27.5 days) than previous reports,5,12 as the patients
were older in our study (73.6 years vs. 55 years). However, the
30-day mortality was only 3% in our study, which was similar
with previous studies.19 Eleven cases (33%) were diagnosed
with coexisting lung abscess in our study. Under the minimally
invasive principle, we did not perform unroofing or pulmonary
resection. We used adequate chest tube position in addition to
the self-ruptured abscess opening in the pleural cavity instead
of extensive eradication of the abscess.
There were some limitations to the current study. This was
a retrospective study with a relatively small sample size.
However, we focused on the elderly group receiving VATS
decortication, which has been less discussed previously. We
still require a larger case number of older patients receiving
VATS decortication to establish a guideline for thoracic em-
pyema treatment in the future.
In conclusion, we think that VATS decortication in the
treatment of thoracic empyema is effective in elderly patients.
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